CEBPA and leukemia: In addition, the metabolite R-2HG caused by isocitrate dehydrogenase (IDH) mutation exerts anti-leukemic effects by inhibiting FTO/m6A/MYC/CEBPA signaling, providing a new target for clinical dosing in the treatment of leukemia.